By searching the publicly available data containing a larger cohort of patients,33 the correlation of lower FOXN3 expression with higher incidence of NPM1 mutation could be confirmed, whereas there was no significant distinction on mutations of DNMT3A, TP53 and ASXL1 between AML with different FOXN3 levels (Figure S4). This evidence concerns the gene FOXN3 and acute myeloid leukemia.